The Safety of Carfilzomib Therapy in Patients on Long-Term Hemodialysis and Multiple Myeloma

Saudi J Kidney Dis Transpl. 2021 May-Jun;32(3):896-897. doi: 10.4103/1319-2442.336794.

Authors

Gioacchino Li Cavoli¹, Anxur Merenda², Onofrio Schillaci¹, Camillo Carollo¹, Carmela Zagarrigo¹, Franca Servillo¹, Mattia Palmeri¹, Tancredi Vincenzo Li Cavoli¹

Affiliations

¹ Department of Nephrology, Dialysis and Renal Transplantation, Civic Hospital, Palermo, Italy.
² Department of Oncohematology, Civic Hospital, Palermo, Italy.

PMID: 35102941
DOI: 10.4103/1319-2442.336794

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Oligopeptides / adverse effects
Renal Dialysis
Thalidomide

Substances

Oligopeptides
Thalidomide
carfilzomib
Dexamethasone